Target intelligence / Profile preview

Chromobox protein homolog 5 (CBX5)

Target
CBX5
Molecular classification
Chromatin-associated protein, Heterochromatin protein family, Epigenetic regulator, Non-histone chromosomal protein, Other
01

Overview

Chromobox protein homolog 5 (CBX5), also known as HP1α, is a highly conserved, non-histone chromatin protein that functions as a key component of constitutive heterochromatin in eukaryotic cells[1][2][3]. CBX5 contains an N-terminal chromodomain that specifically binds trimethylated lysine 9 on histone H3 (H3K9me3), resulting in epigenetic repression and gene silencing[2][3]. The C-terminal chromoshadow domain mediates homodimerization and interaction with other chromatin-associated proteins, supporting the formation and maintenance of repressive chromatin domains and facilitating the assembly of heterochromatin at centromeres and telomeres[1][2][3][4]. CBX5 plays essential roles in genome stability, kinetochore and centromere function during cell division, and DNA damage response, and its dysregulation has been implicated in cancer and other diseases linked to chromatin dysfunction and genome instability[1][2][3]. Notes: - CBX5 itself is not commonly regarded as a classical therapeutic target (e.g., not a receptor, enzyme, transporter, or a routinely drugged protein), but its fundamental roles in epigenetic regulation and frequent upregulation in cancer make it a protein of high biological interest[1][2][3]. - No approved drugs currently directly target CBX5; manipulation of CBX5 or HP1α function is generally indirect, via modulation of histone methylation or chromatin states, which can have broad effects on chromatin and gene expression[1][2].

Other names
HP1αHP1AHP1 alphaHP1HP1-ALPHAHP1alphaAntigen p25HEL25heterochromatin protein 1 homolog alphaepididymis luminal protein 25HP1Hs-alphaHP1Hs alphachromobox homolog 5 (HP1 alpha homolog, Drosophila)
02

Biological functions

Chromatin organizationEpigenetic gene silencingTranscriptional repressionFormation of heterochromatinDNA repair (DNA damage response)Kinetochore formation and chromosome segregationGenome stability
03

Disease associations

CancerOther (related to chromatin dysfunction and genomic instability)
04

Safety considerations

No direct therapeutics; epigenetic/chromatin-targeting in general may have risks of genomic instability and off-target gene silencing

Beyond the preview

Go deeper on Chromobox protein homolog 5 (CBX5).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chromobox protein homolog 5 (CBX5).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call